Alpa Laboratories share news, announcements and annual reports
NSE: ALPABSE: 532878Pharmaceuticals & BiotechnologySmall Cap
Alpa Laboratories Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 2007
Last close ₹50.38down ₹2.24 (4.26%)BSE ₹49.80
Share price at the NSE close on 30 Oct 2026. Previous close ₹52.62.
30 Oct: open ₹51.50, high ₹51.65, low ₹50.00
52-week range of traded prices to 30 Oct 2026
₹46.10Low, 30 Mar 2026₹93.85High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹106 Cr2,659th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.57
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,77166.0% delivered
Alpa Laboratories share news and announcements
363 announcements, routine notices left out, newest first. Page 8 of 8.
Apr 2008
30 Apr · Utilisation of Funds
Vide notes to Accounts in the Unaudited Financial Results for the quarter ended March 31,2008 (taken on record by the Board of Directors of the Company at its meeting held on April 29, 2008) that out of the IPO proceeds of Rs. 6106.81 lacs, the company has utilised 786.43 lacs for IPO expenses, Rs. 2031.57 lacs for Capital expenses & Rs. 500.00 lacs for Working capital. Balance kept in liquid/fixed deposit accounts.21 Apr · Board meeting
To consider and approve the un-audited financial results for the quarter ended March 31, 2008 along with other routine business.
Jan 2008
30 Jan · Utilisation of Funds
Vide notes to Accounts in the Unaudited Financial Results for the quarter ended December 31,2007 (taken on record by the Board of Directors of the Company at its meeting held on January 29, 2008) that out of the IPO proceeds of Rs. 6106.81 lacs, the company has utilised Rs. 786.43 lacs for IPO expenses, Rs. 1950.62 lacs for Capital expenses and Rs. 500.00 lacs for Working capital. Balance has been kept in liquid/fixed deposit accounts.23 Jan · Board meeting
To consider and approve the un-audited financial Results for the quarter ended December 31, 2007 along with other routine business.8 Jan · Change in Company Secretary/Compliance Officer
Our current company secretary and compliance officer, Mr. Mukesh Gupta will no longer be employed at Alpa Laboratories Limited with effect from 17/NOV/2007. We have already started to look for a suitable person for the position of company secretary cum compliance officer and till the time that we find a person, we shall engage the help of a consulting company secretary. In the meantime, Mr. Hemant Jain, our accounts head will act as the compliance officer
Dec 2007
24 Dec · Business
The company has entered into an agreement with Wockhardt Limited to manufacture products for further exports by Wockhardt. Alpa Labs is actively expanding its existing associations by joining hands with reputed parties all over the world12 Dec · Updates
The company has appointed Vhermann Pharmaceutical Inc, Philippines as its agent for distribution of its products already registered in Philippines and to be registered in the future. Vhermann Pharma being a large importer of Drugs and Medicines in Philippines, it expects the volume of the business to reach between USD 4 million to USD 6 million per year. Alpa labs is looking to expand upon its existing sales network by joining hands with reputed parties all over the world
Oct 2007
30 Oct · Utilisation of Funds
Vide notes to Unaudited Financial Results for the quarter & half year ended September 30, 2007 (taken on record by the Board of the directors of the Company at its Meeting held on October 29, 2007) that out of the IPO proceeds of Rs. 6106.81 lacs, the company has utilised Rs. 1938.85 lacs for Capital expenditure and Rs. 786.43 lacs for IPO expenses. The balance as on September 30, 2007 has been kept in liquid/fixed deposit accounts.25 Oct · Board meeting
To consider and approve the un audited financial Results for the quarter /half year ended September 30, 2007 along with other routine business.
Sep 2007
12 Sep · Miscellaneous
The company has appointed Tinez Pharmaceutical Limited, Nigeria as its agent for distribution of its products already registered in Nigeria and to be registered in the future. Tinez Pharma being one of the biggest importers of Drugs and Medicines in Nigeria, it expects the volume of the business to reach between USD 6 million to USD 8 million within a year. Alpa Labs is looking to expand upon its existing sales network by joining hands with reputed parties all over the world
Aug 2007
22 Aug · Miscellaneous
The Company has been allotted 13 locations for setting up Generic Drug Retail Outlets by the Government of Bihar. The expected Annual revenue from these outlets is about Rs. 8 crores and the company expects a net profit of about Rs. 2 crores per year from these outlets. The tender was floated by the State Health Society, Bihar to operate and maintain Generic Drug Shop in each Medical College Hospital, in each of the District Hospital of Bihar, the Sub Divisional Hospital at Barh (Patna) and Gardiner Road Hospital, Patna of its implementation of the National Rural Health Mission (NRHM) to improve the availability of and access to quality health care for people. Alpa Labs is looking to expand upon its existing manufacturing business by venturing into drug retailing14 Aug · News Verification
News Verification : The media had reports that Alpa Laboratories Limited may enter tie-up / JV with Sudan's Marwaco. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Alpa Laboratories Limited has vide its letter inter-alia stated, "We wish to clarify that the company has not issued any press release or disseminated the news item in any other way."14 Aug · News Verification
News Verification : The media had reports that Alpa Laboratories Limited may enter tie-up / JV with Sudan's Marwaco. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Reply is awaited from Alpa Laboratories Limited.